Paola Gargiulo
A5065167427- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Heart Failure Treatment and Management
- Diabetes Treatment and Management
- Lipoproteins and Cardiovascular Health
- Advanced MRI Techniques and Applications
- Cardiovascular and exercise physiology
- Cardiac electrophysiology and arrhythmias
- Cardiac pacing and defibrillation studies
- Heart Rate Variability and Autonomic Control
- Pharmaceutical Economics and Policy
- Hereditary Neurological Disorders
- Cardiovascular Effects of Exercise
- Atrial Fibrillation Management and Outcomes
- Blood Pressure and Hypertension Studies
- Health Systems, Economic Evaluations, Quality of Life
- Pulmonary Hypertension Research and Treatments
- Potassium and Related Disorders
- Cardiac Arrhythmias and Treatments
- Acute Myocardial Infarction Research
- Library Science and Information Systems
- Metabolism, Diabetes, and Cancer
- Cardiomyopathy and Myosin Studies
- Cardiac Valve Diseases and Treatments
- Diabetes Management and Research
Federico II University Hospital
2008-2025
University of Naples Federico II
2013-2025
University of Ferrara
2022
Ecolab (United Kingdom)
2022
Clinica Mediterranea
2020-2021
Tecnologie Avanzate (Italy)
2021
Istituti di Ricovero e Cura a Carattere Scientifico
2007-2019
SDN Istituto di Ricerca Diagnostica e Nucleare
2007-2019
University of Messina
2016
University of Cagliari
2016
Abstract Aims No data are available on early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in patients with acute coronary syndrome (ACS) the real world. This study investigates effects PCSK9i started at time ACS hospitalization lipid control and major cardiovascular (CV) events Methods results The outcome was percentage reaching LDL-C target <55 mg/dL first control. clinical incidence composite CV (all-cause death, non-fatal MI, stroke,...
Abstract Aims The last released European guidelines on the management of heart failure (HF) recommend in patients with chronic HF reduced ejection fraction (HFrEF) a pharmacological approach based four fundamental drugs to be rapidly implemented and then uptitrated modify disease progression. aim Optimization Therapy Italian Management Heart Failure (OPTIMA‐HF) registry is collect data outpatients different settings care. In present analysis, we report first analysis OPTIMA‐HF registry,...
Recent evidence supports the occurrence of multiple hormonal and metabolic deficiency syndrome (MHDS) in chronic heart failure (CHF). However, no large observational study has unequivocally demonstrated its impact on CHF progression outcome. The T.O.S.CA. (Trattamento Ormonale nello Scompenso CArdiaco; Hormone Treatment Heart Failure) Registry been specifically designed to test hypothesis that MHDS affects morbidity mortality patients.The is a prospective, multicentre, involving 19 Italian...
Proprotein Convertase Subtilisin/Kexin type 9 inhibitors (PCSK9i) are recommended in patients at high and very-high cardiovascular (CV) risk, with documented atherosclerotic CV disease (ASCVD), for risk familial hypercholesterolaemia not achieving LDL-cholesterol (LDL-C) goal while receiving maximally tolerated dose of lipid-lowering therapy (LLT). However, single country real-life data, reporting the use PCSK9i clinical practice, limited. Therefore, we designed AT-TARGET-IT, an Italian,...
BACKGROUND AND PURPOSE Sympathetic nervous system (SNS) hyperactivity is characteristic of chronic heart failure (HF) and significantly worsens prognosis. The success β‐adrenoceptor antagonist (β‐blockers) therapy in HF primarily attributed to protection the from noxious effects augmented catecholamine levels. β‐Blockers have been shown reduce SNS HF, but underlying molecular mechanisms are not understood. GPCR kinase‐2 (GRK2)–α 2 adrenoceptor–catecholamine production axis up‐regulated...
Heart failure (HF) with preserved ejection fraction (HFpEF) is a prevalent global condition affecting approximately 50% of the HF population. With aging worldwide population, its incidence and prevalence are expected to rise even further. Unfortunately, until recently, no effective medications were available reduce high mortality hospitalization rates associated HFpEF, making it significant unmet need in cardiovascular medicine. Although HFpEF commonly defined as normal elevated left...
AimsInsulin resistance (IR) represents, at the same time, cause and consequence of heart failure (HF) affects prognosis in HF patients, but pathophysiological mechanisms remain unclear. Hyperinsulinemia, which characterizes IR, enhances sympathetic drive, it can be hypothesized that IR is associated with impaired cardiac innervation HF. Yet, this hypothesis has never been investigated. Aim present observational study was to assess relationship between non-diabetic patients.
Rationale During exercise, heart failure patients (HF) show an out-of-proportion ventilation increase, which in with COPD is blunted. When HF and coexist, the ventilatory response to exercise unpredictable. Objectives We evaluated a human model of respiratory impairment 10 COPD-free healthy subjects, tested progressive workload different added dead space. hypothesized that increased serial space upshifts VE vs. VCO2 relationship VE-axis intercept might be index ventilation. Measurements All...
In patients with heart failure (HF) and reduced ejection fraction (EF), non-invasive cardiac imaging provides diagnostic, prognostic, therapeutic information assists decision-making. The aim of this consensus paper is to provide an overview the clinical applications in management HF systolic dysfunction, mostly focusing on impact decision-making ( Figure 1 ). Figure 1 Use for chronic failure. HF, failure; BNP, brain natriuretic peptide; CMR, magnetic resonance; EF, fraction; CAD,...